CD34 is expressed on human and murine hematopoietic stem and progenitor cells and its clinical usefulness for isolation of stem/progenitor cells has been well established. Although expression of CD34 is regulated in a developmental stage-specific manner, the function of CD34 is not known. Recently we have shown that both a full-length and truncated form of CD34 protein is expressed by hematopoietic cells (Blood 84.591, 1994). To test whether failure to suppress either form of CD34 could affect terminal myeloid ddferentiation, we constitutively expressed these CD34 proteins in murine MI myeloid leukemia cells, which can be terminally differentiated to macrophages by treatment with interleukin-6 of leukemia inhibitory factor. Surprisingly our D34 IS A transmembrane cell surface phosphoprotein that is expressed in a developmental stage-specific manner on the bone marrow (BM)'-4 and vascular endothelial cell^.^.^ BM transplantation studies using CD34' h~m a n , "~ baboon,"' and mouse" cells strongly indicate that CD34 is expressed on the pluripotential lymphohematopoietic stem cell. CD34 is the only available phenotypic surface marker that selectively identifies essentially all lineages of hematopoietic progenitor/stem cells, but is not expressed by morphologically mature hematopoietic cells. The loss of expression of surface CD34 on normal hematopoietic BM progenitor cells is temporally associated with a commitment to differentiate into mature cells that are released into the peripheral blood. Therefore, CD34 may play an important role in the normal developmental program of the earliest lymphohematopoietic cell, including the stem cell.
D34 IS A transmembrane cell surface phosphoprotein that is expressed in a developmental stage-specific manner on the bone marrow (BM)'-4 and vascular endothelial cell^.^.^ BM transplantation studies using CD34' h~m a n , "~ baboon,"' and mouse" cells strongly indicate that CD34 is expressed on the pluripotential lymphohematopoietic stem cell. CD34 is the only available phenotypic surface marker that selectively identifies essentially all lineages of hematopoietic progenitor/stem cells, but is not expressed by morphologically mature hematopoietic cells. The loss of expression of surface CD34 on normal hematopoietic BM progenitor cells is temporally associated with a commitment to differentiate into mature cells that are released into the peripheral blood. Therefore, CD34 may play an important role in the normal developmental program of the earliest lymphohematopoietic cell, including the stem cell.
We and others have sought to identify the function of CD34 through structural studies. Murine and human genomic CD34 DNA and cDNA have been ~l o n e d . '~"~ From the sequence homologies and predicted structural similarities it is expected that human and murine CD34 will function similarly. However, comparison with other genes in the data banks have failed to show any solid clues to suggest the function of CD34. Both murine and human CD34 cDNAs C results show that forced expression of the full-length but not the truncated form of CD34 impedes terminal diffsrentiation by these agents. Because the difference between the two forms of CD34 protein resides in the length of their respective cytoplasmic tail domains, our findings strongly suggest that the cytoplasmic domain region of full-length CD34 is responsible for the observed maturation arrest phenotype. These findings suggest a potential negative regulatory role for full-length CD34 in hematopoietic cell differentiation and may explain, at least in part, the block in maturation observed in CD34+ acute myeloid leukemia.
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predict type 1 transmembrane proteins of -40-kD (385 and 382 amino acids, respectively). The predicted CD34 nucleotide and protein sequences differ significantly between human and murine species in the extracellular domains (only -45% homologous at the amino acid level), but in both species, the CD34 molecule is predicted to be highly glycosylated in the extracellular region. Within the intracellular region, these genes are more highly conserved (190% amino acid identity), predicting a necessary functional importance for this domain.'*"' Interestingly, an alternatively spliced form of the CD34 transcript has been r e p~r t e d '~. '~ and two CD34 proteins, a full-length and a truncated form, have been shown." The mRNA contains an additional exon (Exon X",") which introduces a functional translational stop codon between exons 7 and 8. These exons encode the intracellular domain of CD34. Insertion of this stop codon produces a truncated protein, retaining only 16 of the usual 73 amino acids contained in the murine cytoplasmic region. This difference may account for a differential effect in signal transduction.
Although the transcript for full-length CD34 appears to be expressed in all CD34' cells lines so far tested, expression of the transcript for the truncated CD34 protein is apparently more limited. For example, one human cell line and several cases of primary human AML cells fail to express this truncated form.17 These results raise the question of whether the absence of the truncated CD34 form (which might normally antagonize the effects of full-length CD34) contributes to the maturation arrest phenotype associated with certain CD34' cases of AML.
Although the function of CD34
is not yet known, we postulate that inappropriate expression of CD34 may play a role in the failure of some hematopoietic cells to normally differentiate, resulting in dysregulated hematopoiesis. Therefore, we assessed the effect of forced expression of the fulllength or truncated forms of CD34 on the ability of murine myeloid MI cells'*~** to be induced to terminally differentiate. M1 cells were chosen because the undifferentiated parental cells express CD34 and CD34 is downregulated after induction of differentiation by interleukin-6 (IL-6) or leukem i a inhibitory factor (LIF).I6 In addition, M1 cell differentia-tion can be arrested by the dysregulation of certain hematopoietic transcription factors.2'.z2 Using this system we have found that the full-length and truncated forms of CD34 can produce differential effects on the differentiation program of these cells.
MATERIALS AND METHODS
Inducible cells lines, culture conditions, and cytokines. M1 cells were routinely grown in RPMI-1640 (Whittaker Bioproducts, Inc, Walkersville, MD) containing 5% fetal calf serum (FCS; GIBCO-BRL, Grand Island, NY) and 5% bovine calf serum (CS; HyClone Laboratories. Logan, Utah) supplemented with L-glutamine. Cell cultures were incubated in 5% CO, and passaged twice a week. To induce differentiation, M1 cells were cultured for 3 days in the presence of recombinant murine IL-6 (50 nglmL; GIBCO) or LIF (50 ng/mL; GIBCO) and maintained at < l X 106/mL by the addition of medium containing these cytokines. MI cells were obtained from the American Type Tissue Collection (Rockville, MD).
RNA purijcation and Northern blot analysis. Total RNA was isolated with the acid-guanidium-phenol-chloroform method as described.,' For Northern blot analysis, 15 pg RNA was electrophoresed in a 1.5% formaldehyde gel and transferred to Zeta Probe (Bio-Rad, Hercules, CA). The filters were hybridized with "P-labeled murine CD34 cDNA (exon 2-3-specific, 932 bp) and with murine hypoxanthine-guanine phosphoribosyl transferase (HPRT; 1.3-kb Pst I insert from the pHPT5 plasmid obtained from American Type Culture Collection (ATCC; Rockville, MD) in the presence of 0.5 moVL sodium phosphate, pH 7.2, containing 7% sodium dodecyl sulfate (SDS), 1% bovine serum albumin, and 1 mmom EDTA at 65°C for 16 hours. The filters were washed at 65°C in 0.5 m o m sodium phosphate containing 1% SDS and 1 mmoVL EDTA for 60 minutes, 0.25 mol/L sodium phosphate containing 1% SDS and I mmol/L EDTA for 30 minutes, and 0.1 m o m sodium phosphate containing 0.1% SDS and 1 mmoVL EDTA for 30 minutes and exposed to x-ray films or a Phosphor Screen (Molecular Dynamics, Sunnyvale, CA) for quantitation.
Reverse transcriptase polymerase chain reaction (RT-PCR). Before the RT reaction, for certain samples 6 pg of total RNA was treated with DNAase 1 (50 U; fast protein liquid chromatography purified, Pharmacia, Piscataway, NJ) in 200 pL of I X React 9 (Bethesda Research Laboratories) for 10 minutes at 37°C. After two phenol-chloroform extractions and ethanol precipitation, the samples were dissolved in RT buffer [50 mmoVL TRIS, pH 8.3, 75 mmoY L KCl, 3 mmoVL MgCI,, 10 mmom dithiothreitol, 0.5 mmoVL deoxynucleotide triphosphate (dNTP), 4 U human placental RNase Inhibitor (Boehringer Mannheim, Indianapolis, IN), and 300 ng random hexarners (BRL)]. For the RT reaction, samples were heated in RT buffer to 65°C for 5 minutes cooled on ice, and Moloney murine leukemia virus RT (300 U) was added for 60 minutes at 37°C in a final volume of 30 pL for synthesis of cDNA.
After inactivation of the RT at 95°C for IO minutes, 2 pL of the RT reaction was used as template for a 35-cycle amplification by PCR with CD34-specific primers (see sequences below) in 50 pL PCR reaction buffer (6 mmoVL TRIS, pH 8.3, 1.6 mmol/L NI-bSO,, 1 mmoVL P-mercaptoethanol, 1.5 mmoVL dNTP, and 6 m m o a MgC12). Temperature cycle times were 45 seconds at 9 5 T , 2 minutes at 5 2 T , and 2 minutes at 70°C for 2 cycles, and 2 minutes at 9 5 T , 2 minutes at 5 5 T , and 2 minutes at 70°C for 35 cycles. The reactions were followed by a final 4-minute extension at 70°C. Samples were analyzed by electrophoresis on a 2% agarose gel containing 0.5 pgl mL ethidium bromide. The sequences of the primers used are 5' primer (with an EcoRI site) GAGAATTCGTACAGGAGAD-CAGGTCC, and the 3' primer (with an Xba I site) ACTCTAGAE CBCAG'ITCTGTGTCAGCCAC. The translational start and stop sites are underlined.
Cloning of fill-length and truncated CD34, construction of the mammalian expression vectors, and expression in MI cells. Total RNA from undifferentiated murine embryonic stem cells was transcribed with M-MLV RT using random primers to produce cDNA. The cDNA was then specifically amplified by PCR using a CD34 5' primer with an Eco RI site that spanned the translation start codon, and a 3' primer with an Xba I site that spanned the stop codon (above). The PCR products were restricted with Eco R1 and Xba I, and separated by agarose electrophoresis. The 1,162-bp and 1,318-bp cDNA fragments encoding full-length and truncated CD34, respectively, were isolated. These fragments were directionally subcloned between the shorter version of the murine RNA polymerase I1 (Pol2s) promoter and the bovine growth homone polyadenylation sequence (bpA) contained in the Pol2sneobpA expression plasmid?4 replacing the neo gene. The resulting expression cassette was excised with Xho I, and transferred to the Xho I site in Bluescript I1 SIC+ plasmid for sequencing to verify the identity of the clone. The sequence of each cDNA was found to be identical to published rep o r t~. '~, '~ These plasmids contained the neomycin-resistance cassette derived from Pol2sneobpA. Plasmids (100 pg) containing cDNA encoding full-length or truncated murine CD34 were used to transfect undifferentiated M1 cells (3 X 10') by electroporation (200 V, 960 pF). Appropriate pools and clones of (3418-resistant (200 pg/mL active G418) cells were then evaluated by Northern blot, RT-PCR, and immunofluorescence analyses to verify expression of full-length and truncated CD34.
was constructed from the pHP-MCD43 plasmid that was generously provided by Dr John Frelinger (University of Rochester, NY). For expression in M1 cells, the SV2-neomycin-resistance cassette in the pH@-MCD43 plasmid was replaced with the neomycin-resistance cassette (used above in the CD34 constructs) from Pol2sneobpA. Expression of the CD43 gene was driven by the human @actin promoter.
Cellular phagocytosis assay. MI cells transfected with fulllength or truncated CD34 were cultured for 3 days in the presence of cytokines (50 ng/mL IL-6 or LIF, as indicated) in a 6-well plate (Falcon). Cells (1 X lo5 in 100 pL) were transferred to a 24-well plate (Falcon) and gently agitated for 30 minutes at 37°C with an equal volume of live opsonized Staphylococcus aureus (ATCC 9144, Oxford strain; OD650 = 0.3) as described?' Subsequently, 4 p g of lysostaphin (1 mg/mL; Sigma Chemical CO, St Louis, MO) was added for 5 minutes at 37°C to lyse extracellular bacteria. The percentage of cells containing 2 5 ingested intracellular bacteria was determined by enumeration of a minimum of 300 Wright stained cells from cytospin preparations. Stable constitutive expression of full-length and truncated murine CD34. To address whether downregulation of CD34 is necessary for the terminal differentiation of MI cells, we cloned murine CD34 cDNA and stably expressed either the full-length or the truncated proteins in MI cells. Geneticin-resistant pools of transfected cells were analyzed for expression of the transfected CD34 cDNA transcript by RT-PCR (Fig 2A) . This was performed on total RNA from parental or transfected MI cells using PCR primers that spanned the translational start and stop sites. Products encoding the full-length ( l , 162 bp) or truncated ( 1,3 18 bp) CD34 were detected with ethidium bromide (Fig 2A, arrows at  right) . Increased expression of the appropriate CD34 transcript was confirmed in each pool of the CD34-transfected cell populations. Overexpression of surface protein was detected using rabbit anti-CD34 antiserum" (Fig 2B) . Subsequently, several clones were obtained from the transfected cells. By fluorescence-activated cell sorting analysis, these clones were shown to overexpress CD34 to the same extent as the pooled population (data not shown). The truncated CD34 transcript and protein were expressed more highly than full-length CD34 in both the pooled and cloned transfectants. Recombinant and parental proteins had the FACKLER ET AL same molecular mobilities on SDS polyacrylamide gel electrophoresis as we previously reported for full-length ( 1 IO kD) and truncated (98 kD) CD34" (data not shown). Expression of CD34 cDNA was also confirmed by Northern blot analyses (Fig 2C) . The MI cells showed persistent overexpression of the appropriate CD34 cDNA transcript after exposure to cytokine (IL-6 or LIF) for 3 days (Fig 2C) . In contrast, the endogenous CD34 transcripts were not detected after stimulation of the cells with growth factor. In the transfected cells only very low levels of endogenous transcripts were present. This suggests that there is autoregulation of CD34 expression. For reasons that are unclear, the expression of the CD34 cDNA transcript was enhanced fourfold to sevenfold after exposure of transfected MI cells to either IL-6 or LIF (Fig 2C) , compared with the stably expressed HPRT transcript.
Morphological and functional evidence that full-length, but not truncated, CD34 inhibits terminal differentiation of MI cells. We evaluated whether the forced expression of either form of CD34 protein could affect the hematopoietic differentiation of M 1 cells. Cells were examined for morphologic and functional evidence of terminal differentiation after 3 days in IL-6 or LIF. Parental MI cells and cells transfected with truncated CD34 cDNA (MI,,) or vector only (MInm,) displayed the morphologic features of mature macrophages showing abundant, heavily vacuolated cytoplasm, a reduced nuclearkytoplasmic ratio, distinct heterochromatin, and the lack of prominent nucleoli ( Fig 3A) . In contrast, cells transfected with the full-length CD34 cDNA (MIfull) either remained undifferentiated or displayed an intermediate level of maturation (ie, promonoblast) characterized by minimal vacuolation, a high nuclearkytoplasmic ratio, open chromatin structure, and prominent nucleoli (Fig 3A) . Even after IO days in culture with IL-6 or LIF, these cells failed to terminally differentiate (data not shown). After 6 days the viability of MIfull cells decreased such that continuously growing cultures could not be maintained after induction with IL-6 or LIF (Fig 3B) . In contrast, those cells that were not treated with IL-6 or LIF remained entirely undifferentiated, highly viable, and proliferated at approximately the same rate (Fig 3B) . This indicated that constitutive expression of CD34 did not affect the proliferative program of undifferentiated MI cells. In untreated and IL-6-treated cells, no differences were detected in apoptosis as indicated by DNA ladder formation (evaluated at 0, 2, and 5 days), suggesting that the kinetics of apoptosis was similar in parental and transfected MI cell lines (data not shown).
The acquisition of phagocytic activity is a functional hallmark of terminal macrophage differentiation."," Therefore, MIfull and MI,, were evaluated for their ability to ingest opsonized live staphylococcus aureus (Table l) . After exposure to JL-6 or LIF for 3 days, MIfull cells were practically nonphagocytic. In contrast, parental M I , M l,,, and M l,, cells all showed a significant amount of phagocytic activity. Of particular interest, MI,, cells were highly phagocytic. This observation, that the truncated form of CD34 allowed for terminal differentiation, indicates that the truncated form of CD34 is functionally distinct from the full-length CD34 protein. Clones of M lfull or Ml,, showed the same morphol-ogy (data not shown) and phagocytic activity as their respective pools (Table l ) . Induced MI cells were neither tightly adherent to plastic, nor able to form cellular aggregates, indicating that the overexpression of' CD34 apparently did not enhance the adhesive properties of these cells (data not shown).
To confirm that the block in macrophage differentiation was specifically caused by CD34, MI cells were stably transfected with murine CD43*' (leukosialin/sialophorin). CD43 is a structurally related, highly glycosylated sialomucin that is exclusively expressed on the cell surface of hema- Whether the inhibitory effect of full-length CD34 on MI cell differentiation is cell stage-specific is not known, but is an important issue. As a first attempt to address this, we asked whether the induced differentiation program of certain CD34-cell lines could be inhibited by enforced expression of CD34 (data not shown). The lack of CD34 expression by these cells suggested to us that they may represent a relatively later stage in myeloid cell development (ie, a stage at which CD34 expression has been lost). Furthermore, some of these cells express certain receptors (eg, granulocyte or granulocyte-macrophage colony-stimulating factor [G-CSF or GM-CSF] receptors) which are normally expressed on cells after lineage commitment. Thus. we examined the effect of constitutive expression of murine or human CD34 on two such cell lines, murine 32D and human HL-60 cells. Murine 32D cells are a BM-derived, IL-3-dependent murine cell line that can be induced towards granulocytic differentiation with G-CSF in the absence of IL-3.""" HL-60 promyelocytic leukemia cells can be induced towards granulocytic differentiation with all-trans retinoic acid3" or dimethylsulfoxide:' and towards macrophage differentiation with TPA (12-0-tetradecanoyl-phorbol 1 3-acetate).jX When murine CD34 (full-length or truncated) was constitutively expressed in 32D cells (using the same constructs as above), or human 
IL-6
Neo Vector Only Full-Length CD34
1L-6 Truncated CD34 full-length CD34 was constitutively expressed in HL-60 cells (using a retroviral expression vector), CD34 expression failed to affect terminal differentiation (data not shown). Thus, whereas high-level expression of the CD34 transgene was documented, neither cell line showed a maturation arrest phenotype when induced to differentiate.
DISCUSSION
Our findings indicate that enforced expression of fulllength CD34 inhibits terminal differentiation of murine myeloid MI cells and strongly suggest that CD34 plays a role in the maintenance of a primitive hematopoietic progenitor cell phenotype. This view is consistent with the well-documented loss of CD34 expression that occurs when hematopoietic stendprogenitor cells undergo differentiation and make the transition from morphologically indistinguishable blasts to a later developmental stage when they are recogniz- To evaluate whether suppression of surface CD34 is essential for terminal differentiation of M1 cells, and also whether full-length and truncated CD34 are functionally distinct, transfected M1 cells were treated with IL-6 (50 ng/mLl or leukemia inhibitory factor (LIF; 50 ng/mL) t o induce maturation. Induced or uninduced parental and transfected cells were characterized with respect to morphology, phagocytic activity, and the rate of cellular proliferation. (A) Morphologic analysis. After 3 days of culture in the presence of IL-6, cells were evaluated for morphologic evidence of terminal differentiation. As detected by Wright-Giemsa stain, the majority of parental M1 cells and M1 cells transfected with cDNA encoding truncated CD34 or the neomycin-resistance gene only showed the morphologic features of mature macrophages with a heavily vacuolated cytoplasm, reduced nuclaar/cytoplasmic ratio, distinct heterochromatin, and the lack of prominent nucleoli. In sharp contrast, cells transfected with cDNA encoding full-length CD34 showed evidence of arrested maturation, in which most cells had the appearance of promonoblasts or undifferentiated blasts. Control cells that were not cultured with IL-6 remained entirely undifferentiated. These results suggest that full-length, but not truncated, CD34 can suppress terminal differentiation of M1 cells. 
DAYS
Because the loss of CD34 expression has been reported to coincide with the terminal maturation of normal and leukemic blood and BM cells, the suppression of CD34 expression may be essential and play a role in regulating the normal maturation process. Of particular interest, any inhibitory effect of full-length CD34 on MI cell development appears to be manifest only after the differentiation program has been initiated. Undifferentiated MI, Mlfun, Ml,, or Ml,, cells all proliferate at the same rate, have identical morphologic appearances, and do not exhibit phagocytosis in the absence of IL-6 or LIF.
In contrast with our studies in MI cells, the differentiation programs of two CD34-cell lines, murine 32D and human HL60 cells, were unaffected by constitutive expression of either form of CD34. Although these studies are limited to only two CD34-myeloid cell lines, they raise the intriguing and distinct possibility that CD34 exerts its regulatory effect mainly on early stage cells, because loss of CD34 expression is normally a marker of more lineage-committed cells. These data have lead us to speculate that there may be a stage in differentiation beyond which the differentiation program of myeloid cells is incapable of responding to any negative regulatory signals generated by full-length CD34. Although highly speculative, it is also possible that CD34 may play a role in a specific cytokine signaling pathways (ie, activated Any difference in the functional consequence of enforced overexpression of full-length and truncated CD34 proteins is likely to be caused by differences in their cytoplasmic by 1L-6LIF/g~l30). domains because both forms are apparently structurally identical in the extracellular domain.12"' Several potential sites within the cytoplasmic domain that are contained only in the full-length protein could contribute to this phenotype. Because PKC is known to be involved in hematopoietic cell proliferation and differentiati~n,~~.~' it is possibly significant that there are two potential PKC target sites, at least one of which we have shown to be used in normal and leukemic ~e l l s .~' .~~ We have shown that there is also a possible phosphorylation site33 for glycogen synthase LII, a serine kinase that has recently been shown to be involved in cell growth ~o n t r o l .~~,~~ A role for these sites will be further explored.
M1 For example, promyelocytes, promonoblasts, promegakaryoblasts, and pre-pre-B cells can be isolated in the CD34' fraction using anti-CD34 antibodies (unpublished results, 1982) . In contrast, the more mature cell types in each lineage do not express CD34. In our studies, induced Mlmlr cells arrest precisely at the morphologic stage in differentiation at which normal surface expression of CD34 is lost. Therefore, we speculate that certain specific cellular events may occur at this stage that involve CD34 and are critical for the cellular commitment to make the transition towards terminal differentiation. It would follow that perturbation of these events might block terminal differentiation, such as occurs in the maturation arrest phenotype displayed by acute leukemias. Although further studies are needed to determine if normal hematopoietic progenitor cells respond to the constitutive expression of full-length CD34 in a manner similar to M1 cells, CD34 may play an important role in this process.
